ALFA FinderBSE filing, NSE: ALIVUS. Summary written from the filing by ALFA Finder's alert engine.
Alivus Life Sciences Ltd: key numbers
- Share price
- ₹1,480.60
- Market cap
- ₹18,207 Cr
- Revenue (annual)
- ₹2,552 Cr
- Net profit (annual)
- ₹564.5 Cr
- P/E (TTM)
- 27.2×Sector 43.0×
- Promoter holding
- 74.85%-0.02% QoQ
- FII holding
- 5.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alivus Life Sciences Ltd
All →Alivus Life Sciences Promoter Selling
Nirma Limited, a promoter of Alivus Life Sciences, sold 36,80,000 shares (2.99%) in the open market on 6 November 2026. Promoter holding falls from 74.73% to 71.74%.
Alivus Life Sciences Earnings Call Transcript: Key Takeaways
Alivus reported strong revenue growth driven by new products and CDMO traction, though margins were inflated by one-time income.
- Call
- Guides 11% growth
Alivus Life Sciences Employee Stock Options
Alivus Life Sciences allotted 1,95,833 equity shares to an employee who exercised ESOP options under its 2021 scheme. Paid-up capital rises to Rs. 24.59 Crore.
Alivus Life Sciences Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹6,820 Mn (+16.0% YoY), EBITDA ₹2,851 Mn (41.8% margin), PAT ₹1,968 Mn (+51.3% YoY). Non-GPL growth and CDMO pickup drove results.
Alivus Life Sciences Results Update
Alivus Life Sciences reported Q2FY27 revenue of Rs. 6,820 Mn (up 16.0% YoY) and PAT of Rs. 1,968 Mn in a press release. Investors see record EBITDA margins of 41.8% and capex progress at Solapur and Taloja.
Alivus Life Sciences Q2 FY27 Results: Net Profit ₹196.7 Cr, Up 51.3% YoY
Alivus Life Sciences Ltd reported revenue from operations of ₹682 Cr (+16.0% YoY) and net profit of ₹196.7 Cr (+51.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹196.7 Cr · +51.3% YoY
Other business update announcements
All →Italian Edibles Business Update
Italian Edibles revised its project timeline again, pushing commercial production from January 2027 to April 2027. Construction delays stem from steel prices, supply chain disruption, weather and labour shortages.
- Execution
- Commercial production revised to April 2027 from January 2027
Bajaj Finserv Business Update
Bajaj Finserv disclosed October 2026 monthly premium and new business data for its unlisted insurance subsidiaries. The figures are provisional.
Bajaj Finance Business Update
Bajaj Finance submitted its Half Yearly Report for FY2026-27 covering the six months to 30 September 2026. The report shows 28% consolidated PAT growth to ₹12,447 crore and a planned ₹17,500 crore capital raise.
Cohance Lifesciences Business Update
Cohance Lifesciences disclosed that USFDA issued the Establishment Inspection Report for its Pashamylaram facility, classifying the inspection as Voluntary Action Indicated. The inspection is now concluded.
Religare Enterprises Business Update
Religare Finvest, a material subsidiary, resumed lending after RBI lifted its Corrective Action Plan. It disbursed its first Loan Against Property on 6 November 2026.
Purple Wave Infocom Business Update
Purple Wave signed a 5-year data integration agreement with BPCL for its Hygiair devices. The Rs 10 crore figure is indicative, not firm order value.
- Execution
- 5 years